Newline

Newline Therapeutics is a biotechnology company focused on developing next-generation small molecule inhibitors for the treatment of genetically defined cancers. The company's primary focus is on the Menin-KMT2A (MLL) interaction, a critical driver in several aggressive forms of leukemia and certain solid tumors. By utilizing advanced medicinal chemistry and structural biology, Newline aims to create highly potent and selective therapies that overcome the limitations of first-generation inhibitors. Their lead programs are currently in the pre-clinical stage, targeting acute leukemias with KMT2A rearrangements or NPM1 mutations.